```html

Zoster Ophthalmicus (Eye Involvement)

What is Zoster Ophthalmicus (Eye Involvement)?

Zoster ophthalmicus (ZO) refers to the re‑activation of the varicella‑zoster virus (VZV) in the ophthalmic branch of the trigeminal nerve (cranial nerve V1). When the virus involves the eye or its surrounding structures, it can cause a spectrum of ocular complications ranging from mild conjunctivitis to sight‑threatening keratitis, uveitis, and optic neuritis. Because the eye is a delicate organ with limited capacity to tolerate inflammation, prompt recognition and treatment are essential.

In lay terms, ZO is “shingles that affects the eye.” The classic skin rash of shingles appears on the forehead, upper eyelid, or bridge of the nose, often accompanied by eye pain, redness, and visual changes. If left untreated, the infection can lead to permanent vision loss.

Common Causes

The underlying cause is always the same virus, but several factors increase the risk that VZV will reactivate in the ophthalmic division and involve the eye.

• Prior chickenpox infection: The virus remains dormant in sensory ganglia after the initial illness.
• Advanced age: Immunity wanes after age 50, making reactivation more likely.
• Immunosuppression: HIV/AIDS, organ transplantation, chemotherapy, or long‑term steroids.
• Chronic diseases: Diabetes, chronic kidney disease, and malignancies.
• Stress or severe illness: Physical or emotional stress can trigger viral re‑emergence.
• Trauma to the face or eye: Local injury may disturb nerve tissue.
• Vaccination status: Lack of shingles (herpes zoster) vaccine in adults over 50.
• Auto‑immune disorders: Conditions such as rheumatoid arthritis that require immunosuppressive therapy.
• Seasonal variation: Higher incidence in winter months when viral respiratory infections are common.
• Genetic susceptibility: Certain HLA types have been linked to more severe VZV reactivations.

Associated Symptoms

Eye involvement usually does not occur in isolation; patients often experience a constellation of systemic and ocular signs.

• Dermatomal rash: Grouped vesicles on the forehead, scalp, or upper eyelid—often following the “V1” distribution.
• Ocular pain: Burning, throbbing, or stabbing pain that may precede the rash by several days.
• Conjunctival injection: Redness of the white of the eye.
• Keratitis: Corneal inflammation causing photophobia, tearing, and blurred vision.
• Uveitis: Inflammation of the iris and ciliary body, leading to eye pain, light sensitivity, and hazy vision.
• Episcleritis or scleritis: Inflammation of the deeper white of the eye, often painful.
• Acute retinal necrosis: Rare but serious condition causing vision loss.
• Ptosis or eyelid swelling: Drooping eyelid or edema due to nerve involvement.
• Reduced visual acuity: Any new blurriness, double vision, or “dark spot” in the visual field.
• Post‑herpetic neuralgia: Persistent burning pain after the rash resolves.

When to See a Doctor

Because ocular complications can progress rapidly, seek professional care promptly if you notice any of the following:

• Rash or vesicles on the forehead, nose bridge, or around the eye.
• Severe eye pain, especially if it is worsening or not relieved by over‑the‑counter pain meds.
• Redness, tearing, or a gritty sensation in the eye.
• New or worsening blurry vision, double vision, or loss of part of your visual field.
• Photophobia (intolerance to light) that interferes with daily activities.
• Swelling or drooping of the eyelid.

If you belong to a high‑risk group (immunocompromised, over 60, diabetic), act even sooner—early antiviral therapy dramatically reduces the risk of permanent damage.

Diagnosis

Diagnosis of Zoster Ophthalmicus combines a detailed history, physical examination, and targeted tests.

Clinical Evaluation

• History: Recent shingles rash, previous chickenpox, immunization status, and systemic illnesses.
• Visual acuity test: Determines baseline vision.
• Slit‑lamp examination: Allows the ophthalmologist to view the cornea, conjunctiva, iris, and anterior chamber for vesicles, inflammation, or epithelial defects.
• Fundoscopic exam: Looks at the retina and optic nerve for signs of necrosis or vasculitis.
• Palpebral (eyelid) inspection: Checks for vesicles on the lid margin or nasociliary branch involvement (Hutchinson’s sign).

Laboratory & Ancillary Tests

• Polymerase chain reaction (PCR) of lesion fluid: Highly sensitive for VZV DNA.
• Direct fluorescent antibody (DFA) staining: Rapid bedside test for viral antigens.
• Serology: May be used in atypical cases, though less specific.
• Corneal staining with fluorescein: Highlights epithelial breakdown.
• Imaging (OCT, MRI): Optical coherence tomography can assess retinal layers; MRI may be ordered if optic nerve involvement is suspected.

Treatment Options

The primary goal is to stop viral replication, control inflammation, and protect the ocular surface.

Antiviral Medications

• Acyclovir: 800 mg five times daily for 7–10 days (oral) – standard first‑line.
• Valacyclovir: 1 g three times daily – easier dosing with similar efficacy.
• Famciclovir: 500 mg three times daily – alternative for patients with renal issues.
• Intravenous acyclovir: 10‑15 mg/kg every 8 hours for immunocompromised patients or severe ocular disease.

Antivirals should be started within 72 hours of rash onset for maximal benefit, but treatment is still recommended even after this window because ocular complications can arise later.

Corticosteroids

• Topical prednisolone acetate (1%) drops – reduce anterior segment inflammation.
• Oral prednisone (0.5 mg/kg) in selected cases – must be paired with antiviral therapy.
• Periocular or intravitreal steroids – reserved for severe uveitis or retinal involvement under specialist supervision.

Adjunctive Eye Care

• Lubricating eye drops (preservative‑free): Prevent corneal drying.
• Therapeutic contact lenses or bandage lenses: Protect a compromised corneal surface.
• Topical antibiotics: Used prophylactically if a corneal ulcer is present.
• Pain control: Acetaminophen, NSAIDs, or neuropathic agents (gabapentin, pregabalin) for post‑herpetic neuralgia.

Home & Supportive Measures

• Apply cool compresses to the forehead/eyelid to relieve pain.
• Avoid rubbing the eye – can spread the virus.
• Maintain strict hand hygiene; wash hands frequently.
• Stay hydrated and rest to support immune function.

Prevention Tips

• Shingles vaccine (Shingrix): Recombinant zoster vaccine is >90 % effective at preventing shingles and post‑herpetic neuralgia. Recommended for adults ≥50 years and for immunocompromised adults after discussing with a physician.
• Varicella vaccine: Ensures primary immunity in those without a history of chickenpox.
• Blood sugar control: Tight glucose management reduces VZV reactivation risk in diabetics.
• Immune health: Adequate sleep, balanced diet, regular exercise, and stress reduction.
• Avoid exposure: People with active shingles should keep lesions covered and avoid close contact with immunocompromised individuals, pregnant women, and newborns.
• Prompt treatment of early shingles: Starting antivirals within 72 hours can prevent ocular spread.

Emergency Warning Signs

Key Takeaways

• Zoster ophthalmicus is shingles that affects the eye and can threaten vision.
• Early antiviral therapy (within 72 hours) and, when indicated, steroids are the mainstay of treatment.
• Prompt evaluation by an eye‑care specialist is critical; do not wait for symptoms to improve on their own.
• Vaccination (Shingrix) is the most effective preventive strategy for adults over 50.
• Red‑flag symptoms—especially sudden vision loss—require immediate emergency care.

For the most up‑to‑date guidance, consult reputable sources such as the Mayo Clinic, CDC, NIH, and the World Health Organization.

```